Prolonged complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse. 1978

F R Appelbaum, and A B Deisseroth, and R G Graw, and G P Herzig, and A S Levine, and I T Magrath, and P A Pizzo, and D G Poplack, and J L Ziegler

Fourteen patients with American Burkitt's lymphoma resistant to conventional chemotherapy were treated with high-dose combination chemotherapy and intensive supportive care. Four patients died shortly after chemotherapy, 3 of an acute carditis. All ten remaining patients demonstrated tumor regression and 3 remain in prolonged complete unmaintained remission 29+, 19+, and 9+ months after treatment. These findings demonstrate that high-dose chemotherapy will benefit some patients with Burkitt's lymphoma unresponsive to conventional chemotherapy, but the medullary and extramedullary toxicity of this treatment strategy remains a formidable obstacle.

UI MeSH Term Description Entries
D008297 Male Males
D009205 Myocarditis Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies. Carditis,Myocarditides
D012075 Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment. Spontaneous Healing,Spontaneous Regression,Spontaneous Remission,Healing, Spontaneous,Regression, Spontaneous,Spontaneous Healings,Spontaneous Regressions
D002051 Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative. African Lymphoma,Burkitt Cell Leukemia,Burkitt Tumor,Lymphoma, Burkitt,Burkitt Leukemia,Burkitt's Leukemia,Burkitt's Lymphoma,Burkitt's Tumor,Leukemia, Lymphoblastic, Burkitt-Type,Leukemia, Lymphocytic, L3,Lymphocytic Leukemia, L3,Burkitts Leukemia,Burkitts Lymphoma,Burkitts Tumor,L3 Lymphocytic Leukemia,L3 Lymphocytic Leukemias,Leukemia, Burkitt,Leukemia, Burkitt Cell,Leukemia, Burkitt's,Leukemia, L3 Lymphocytic,Lymphoma, African,Lymphoma, Burkitt's,Tumor, Burkitt,Tumor, Burkitt's
D002330 Carmustine A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) BCNU,1,3-Bis(2-Chloroethyl)-1-Nitrosourea,BiCNU,FIVB,N,N'-Bis(2-Chloroethyl)-N-Nitrosourea,Nitrumon
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

F R Appelbaum, and A B Deisseroth, and R G Graw, and G P Herzig, and A S Levine, and I T Magrath, and P A Pizzo, and D G Poplack, and J L Ziegler
May 1984, Cancer treatment reports,
F R Appelbaum, and A B Deisseroth, and R G Graw, and G P Herzig, and A S Levine, and I T Magrath, and P A Pizzo, and D G Poplack, and J L Ziegler
January 1990, Presse medicale (Paris, France : 1983),
F R Appelbaum, and A B Deisseroth, and R G Graw, and G P Herzig, and A S Levine, and I T Magrath, and P A Pizzo, and D G Poplack, and J L Ziegler
February 1975, Cancer,
F R Appelbaum, and A B Deisseroth, and R G Graw, and G P Herzig, and A S Levine, and I T Magrath, and P A Pizzo, and D G Poplack, and J L Ziegler
January 2002, Haematologica,
F R Appelbaum, and A B Deisseroth, and R G Graw, and G P Herzig, and A S Levine, and I T Magrath, and P A Pizzo, and D G Poplack, and J L Ziegler
April 1976, International journal of cancer,
F R Appelbaum, and A B Deisseroth, and R G Graw, and G P Herzig, and A S Levine, and I T Magrath, and P A Pizzo, and D G Poplack, and J L Ziegler
January 1985, Cancer investigation,
F R Appelbaum, and A B Deisseroth, and R G Graw, and G P Herzig, and A S Levine, and I T Magrath, and P A Pizzo, and D G Poplack, and J L Ziegler
December 1985, [Rinsho ketsueki] The Japanese journal of clinical hematology,
F R Appelbaum, and A B Deisseroth, and R G Graw, and G P Herzig, and A S Levine, and I T Magrath, and P A Pizzo, and D G Poplack, and J L Ziegler
January 1979, Medical and pediatric oncology,
F R Appelbaum, and A B Deisseroth, and R G Graw, and G P Herzig, and A S Levine, and I T Magrath, and P A Pizzo, and D G Poplack, and J L Ziegler
February 1988, Presse medicale (Paris, France : 1983),
F R Appelbaum, and A B Deisseroth, and R G Graw, and G P Herzig, and A S Levine, and I T Magrath, and P A Pizzo, and D G Poplack, and J L Ziegler
December 2009, World journal of gastroenterology,
Copied contents to your clipboard!